Page 41 - Pivotal Program Progress News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pivotal program progress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pivotal Program Progress Today - Breaking & Trending Today

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure. | May 3, 2023 ....

United States , David Chang , Christine Cassiano , Allogene Allo , Timothy Moore , American Association Of Cancer Research , Drug Administration , American Association For Cancer Research , Allocart Program , Allogene Therapeutics Inc , American Society Of Clinical Oncology , Enrollment Ongoing , First Potentially Pivotal Phase , Refractory Largeb Cell , Support Licensure , Lymphodepleting Agent , American Society , Clinical Oncology , Annual Meeting Presentation , Interim Phase , Renal Cell Carcinoma , American Association , Cancer Research , Annual Meeting , Provide Proof Of Concept , Partial Response Following ,

Vivasure Medical Announces Enrollment of First Patients in Pivotal PATCH Study

Study will evaluate the safety and efficacy of Vivasure's PerQseal Closure Device System designed for large arteriotomies Vivasure Medical, a company pioneering novel fully absorbable technology ....

New York , United States , Erich Sandoval , William Gray , Vijay Iyer , University Of Buffalo , Kaleida Health Buffalo , Lankenau Heart Institute , Drug Administration , Gates Vascular Institute In Buffalo , Main Line Health , Perqseal Closure Device System , Vivasure Perqseal Closure Device , Kaleida Health , Structural Heart Interventions , Buffalo General ,

Vifor International AG (CSL Vifor): Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment ....

Steve Pascoe , Fresenius Medical Care , Dual Endothelin Angiotensin Receptor Antagonist , Senior Vice President , Therapeutic Area Strategy , Efficacy Endpoints , Two Year Exploratory Endpoints , Travere Therapeutics , Vifor Fresenius Medical Care Renal Pharma ,

Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data

By Colin Kellaher

Shares of Travere Therapeutics tumbled nearly 35% and hit a new 52-week low Tuesday after the biopharmaceutical company said a pivotal Phase 3 study of its kidney drug. | May 2, 2023 ....

San Diego , United States , Jingming Chen , Colin Kellaher , Liisa Bayko , European Medicines Agency , Drug Administration , Travere Therapeutics , Wall Street , Laura Chico , Dow Jones , Nc Stock Exchange , Press Release , Idney Tvtx Us89422g1076 ,

Teako Minerals Launches the Service Alliance

TEAKO MINERALS CORP. , is pleased to announce the creation of The Service Alliance. Valence Mining Services , established by Teako Minerals Corp. , will play a pivotal role in hosting The Service. | May 1, 2023 ....

British Columbia , United Kingdom , Sven Gollan , Current Service Alliance Members , Exploration Companies , Financing Companies , Ekometall Exploration Ltd , Technology Companies , Teako Minerals Corp , Service Alliance , Refex Group , Valence Mining Services , Service Alliance Members , Teako Minerals , Company Or Teako , British Columbia Newsfile Corp , Capella Minerals , Commander Resources , District Metals , Finex Metals , Pegasus Resources , Playfair Mining , Sego Resources , Junior Mining Hub , Coring Company , Axino Capital ,